ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM: Abstract Number: 1372

Upadacitinib and Other JAK Inhibitors in the Treatment of Rheumatoid Arthritis – Interstitial Lung Disease. National Multicenter Study Clinical Practice.

RA – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1370

Upadacitinib vs TNFi and Other JAKi Treatment Outcomes in Australian Rheumatoid Arthritis Patients: Descriptive Comparison of Persistence and Effectiveness Using the OPAL Dataset

RA – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 0982

Urinary Incontinence Among Individuals with Systemic Lupus Erythematosus

Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1534

Use and Safety of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients with Lupus Nephritis and Clinical Indications

SLE – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1011

Use of the Shingrix Vaccine Among Patients with Inflammatory Arthritis and Risk of Cardiovascular Events Following Herpes Zoster

Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1294

Using Case-Based Continuing Education to Identify and Address Knowledge and Behavior Gaps in ANCA-associated Vasculitis

Professional Education Poster

10:30AM-12:30PM: Abstract Number: 1410

Using Social Listening to Understand the Patient Voice: The Daily Impacts of Sjögren’s Disease

Sjögren's Syndrome – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 1342

Utility of Anti-Carbamylated Antibodies in Early Rheumatoid Arthritis in South Asian Population

RA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1061

Utilization of Electronic Health Record System to Improve Glucocorticoid Induced Osteoporosis Screening and Treatment

Measures & Measurement of Healthcare Quality Poster

10:30AM-12:30PM: Abstract Number: 1054

Utilization of Rehabilitation Services in Patients with Common Rheumatic Conditions: A Systematic Review

Health Services Research – ACR/ARP Poster II

10:30AM-12:30PM: Abstract Number: 1526

Utilizing Electronic Health Records to Identify Clinical Features of ANA-Positive Patients Imparting High Risk for Progression to Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1604

Utilizing Machine Learning with Claims Data to Diagnose and Quantify the Prevalence of Eosinophilic Granulomatosis with Polyangiitis

Vasculitis – ANCA-Associated Poster II

10:30AM-12:30PM: Abstract Number: 0929

UVB-Induced Keratinocyte-Derived Extracellular Vesicles: Cytokeratin 10 as a Marker of Epidermal Origin

Innate Immunity Poster

10:30AM-12:30PM: Abstract Number: 1461

Uveitis in Axial Spondyloarthritis: Study of 309 Patients in a Single University Center

SpA Including PsA – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 0977

Vaccine Effectiveness and Safety of Recombinant Zoster Vaccine (RZV) in Rheumatoid Arthritis (RA) Patient Populations Aged 50 Years and Older

Epidemiology & Public Health Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].